Related Experiment Videos
Low-dose radiation plus rapamycin promotes long-term bone marrow chimerism.
Jonathan D Powell1, Courtney Fitzhugh, Elizabeth M Kang
1Department of Oncology, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Transplantation
|December 24, 2005
Summary
Rapamycin (RAPA) promotes donor chimerism in mice without toxic conditioning, offering a new path for stem cell transplants. This nonmyeloablative approach shows promise for treating non-malignant diseases like hemoglobinopathies.
Area of Science:
- Immunology
- Transplantation Biology
- Hematology
Background:
- Nonmyeloablative conditioning advances allogeneic stem cell transplantation, expanding its use to non-malignant diseases.
- Optimal conditioning regimens for these transplants remain undetermined.
- Rapamycin (RAPA) has shown potential in promoting T-cell tolerance.
Purpose of the Study:
- To evaluate the efficacy of rapamycin (RAPA) and cyclosporine A (CSA) in promoting chimerism in a murine haploidentical bone marrow transplantation model.
- To determine if RAPA or CSA can facilitate donor engraftment without myeloablative conditioning.
Main Methods:
- Mice underwent conditioning with 300 cGy irradiation.
- Groups received either RAPA (3 mg/kg/day), CSA (20 mg/kg/day), or no immunosuppression for 4 weeks post-transplant.
- Chimerism and toxicity were monitored.
Main Results:
- No apparent toxicity was observed in any group.
- Animals maintained normal blood counts throughout the study.
- Long-term macrochimerism was exclusively observed in the RAPA-treated group.
Conclusions:
- A simple, non-toxic, irradiation-based regimen using RAPA facilitates engraftment without ablation.
- This RAPA strategy may be beneficial for non-malignant disorders, such as hemoglobinopathies, where donor chimerism can be curative.